Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boehringer's Ofev, Roche's Esbriet win same-day IPF approvals

This article was originally published in Scrip

Executive Summary

The FDA played no favorites in the idiopathic pulmonary fibrosis (IPF) space – approving two new medicines on the same day on 15 October for the fatal lung disease, Boehringer Ingelheim's Ofev (nintedanib) and Roche's Esbriet (pirfenidone), despite the different timelines the drugs were on for the agency's nod.

You may also be interested in...



Sandoz Launches First US Pirfenidone At-Risk After Court Triumphs

Sandoz has introduced the first generic version of Roche’s landmark treatment for idiopathic pulmonary fibrosis, Esbriet (pirfenidone), after downing the originator’s attempts to stymie its launch.

Endeavor Launches With $62m And A Hedgehog Inhibitor From Lilly

John Hood spent the past few years looking for a drug candidate worth forming a new company around before he zeroed in on Lilly’s taladegib as a treatment for idiopathic pulmonary fibrosis. 

Boehringer Ingelheim's Partnering Focus: An Interview With Ioannis Sapountzis

Trying to catch up with peers in both immuno-oncology and NASH, the German pharma has assigned Sapountzis to lead its US business development efforts. At BIO, he outlined his strategy and goals.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC026639

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel